【摘要】 目的观察内异丸合内异灌肠液联合治疗子宫内膜异位症的疗效,并探讨其对抗子宫膜抗体(EMAB)和癌抗原125(CA125)的影响。方法对58例诊断为子宫内膜异位症的患者,采用随机单盲的研究方法分成3组,A组(采用内异丸口服)16例;B组(内异丸口服加内异灌肠液灌肠)24例;C组(采用丹那唑口服)18例,3组均连续治疗3个月经周期后进行疗效评定,并检测3组治疗前后血清EMAB与CA125。结果3组临床疗效比较B组优于C组(P<0．05),A组优于C组(P<0．05),B组与A组比较差异无显著性(P>0．05);3组EMAB和CA125治疗前后差异无显著性(P>0．05)。结论内异丸合内异灌肠液可增强治疗子宫内膜异位症的疗效;但对EMAB和CA125无明显影响。更多还原

【Abstract】 Objective To observe the effect of combined therapy of Neiyi pill (NP) and Neiyi enema (NE) on endometriosis and its effect on serum levels of endometrial antibody (EMAB) and carcinoembryonic antigen 125 (CA125). Methods Fifty-eight cases with endometriosis were divided into 3 groups randomly, group A (n - 16) treated by NP, group B (n =24) treated by NP and NE, and group C (n = 18) treated by danazol, all for 3 menstrual cycle with single blind method. The effect was observed and the serum levels of EMAB and CA125 were detected before and after treatment. Results Comparison of the efficacy between the 3 groups showed: there was no remarkable difference between group A and B (P>0.05), both of group A and group B were superior to that of group C (P<0.05). The levels of EMAB and CA125 had no significant changes in all the three groups after treatment. Conclusion Combined therapy of NP and NE could improve the curative effect on endometriosis, and without obvious effects on serum levels of EMAB and CA125.更多还原